Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
Abstract Background The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear. The aim of our real-world cohort study was to evaluate the c...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-01-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12933-017-0655-y |
| _version_ | 1811284065112817664 |
|---|---|
| author | Yan-Rong Li Sung-Sheng Tsai Dong-Yi Chen Szu-Tah Chen Jui-Hung Sun Hung-Yu Chang Miaw-Jene Liou Tien-Hsing Chen |
| author_facet | Yan-Rong Li Sung-Sheng Tsai Dong-Yi Chen Szu-Tah Chen Jui-Hung Sun Hung-Yu Chang Miaw-Jene Liou Tien-Hsing Chen |
| author_sort | Yan-Rong Li |
| collection | DOAJ |
| description | Abstract Background The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear. The aim of our real-world cohort study was to evaluate the cardiovascular outcomes of linagliptin in patients with T2DM after ACS or AIS. Methods An open observational noncrossover retrospective cohort study was conducted between June 1, 2012 and December 31, 2013 utilizing Taiwan National Health Insurance Research Database. A total of 1203 patients with T2DM after ACS or AIS were selected as the study cohort. Cardiovascular safety and efficacy of linagliptin were evaluated by comparing outcomes of 401 subjects receiving linagliptin after ACS or AIS to 802 matched control subjects not receiving any incretin-based therapy after ACS or AIS. The primary composite outcome included cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke. Results The primary composite outcome after 15-month follow-up was 7% (28 patients) in the linagliptin group compared with 6.1% (49 patients) in the control group [hazard ratio (HR) 1.06; 95% confidence interval (CI) .66–1.68]. The linagliptin group also had similar risks of all-cause mortality, hospitalization for heart failure, percutaneous coronary intervention and coronary artery bypass grafting compared to the control group in terms of the secondary outcomes. Conclusions In T2DM patients after ACS or AIS, treatment with linagliptin was not associated with increased risks of cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke. |
| first_indexed | 2024-04-13T02:22:58Z |
| format | Article |
| id | doaj.art-615a34b7a925449182d45d9229dd604f |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-04-13T02:22:58Z |
| publishDate | 2018-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-615a34b7a925449182d45d9229dd604f2022-12-22T03:06:52ZengBMCCardiovascular Diabetology1475-28402018-01-0117111310.1186/s12933-017-0655-yLinagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic strokeYan-Rong Li0Sung-Sheng Tsai1Dong-Yi Chen2Szu-Tah Chen3Jui-Hung Sun4Hung-Yu Chang5Miaw-Jene Liou6Tien-Hsing Chen7Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial HospitalDivision of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial HospitalDivision of Cardiology, Department of Internal Medicine, Chang Gung Memorial HospitalDivision of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial HospitalDivision of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial HospitalDivision of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial HospitalDivision of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial HospitalDivision of Cardiology, Department of Internal Medicine, Chang Gung Memorial HospitalAbstract Background The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear. The aim of our real-world cohort study was to evaluate the cardiovascular outcomes of linagliptin in patients with T2DM after ACS or AIS. Methods An open observational noncrossover retrospective cohort study was conducted between June 1, 2012 and December 31, 2013 utilizing Taiwan National Health Insurance Research Database. A total of 1203 patients with T2DM after ACS or AIS were selected as the study cohort. Cardiovascular safety and efficacy of linagliptin were evaluated by comparing outcomes of 401 subjects receiving linagliptin after ACS or AIS to 802 matched control subjects not receiving any incretin-based therapy after ACS or AIS. The primary composite outcome included cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke. Results The primary composite outcome after 15-month follow-up was 7% (28 patients) in the linagliptin group compared with 6.1% (49 patients) in the control group [hazard ratio (HR) 1.06; 95% confidence interval (CI) .66–1.68]. The linagliptin group also had similar risks of all-cause mortality, hospitalization for heart failure, percutaneous coronary intervention and coronary artery bypass grafting compared to the control group in terms of the secondary outcomes. Conclusions In T2DM patients after ACS or AIS, treatment with linagliptin was not associated with increased risks of cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke.http://link.springer.com/article/10.1186/s12933-017-0655-yLinagliptinDipeptidyl peptidase-4 (DPP-4) inhibitorType 2 diabetes mellitusAcute coronary syndromeAcute ischemic strokeCardiovascular outcome |
| spellingShingle | Yan-Rong Li Sung-Sheng Tsai Dong-Yi Chen Szu-Tah Chen Jui-Hung Sun Hung-Yu Chang Miaw-Jene Liou Tien-Hsing Chen Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke Cardiovascular Diabetology Linagliptin Dipeptidyl peptidase-4 (DPP-4) inhibitor Type 2 diabetes mellitus Acute coronary syndrome Acute ischemic stroke Cardiovascular outcome |
| title | Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke |
| title_full | Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke |
| title_fullStr | Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke |
| title_full_unstemmed | Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke |
| title_short | Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke |
| title_sort | linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke |
| topic | Linagliptin Dipeptidyl peptidase-4 (DPP-4) inhibitor Type 2 diabetes mellitus Acute coronary syndrome Acute ischemic stroke Cardiovascular outcome |
| url | http://link.springer.com/article/10.1186/s12933-017-0655-y |
| work_keys_str_mv | AT yanrongli linagliptinandcardiovascularoutcomesintype2diabetesafteracutecoronarysyndromeoracuteischemicstroke AT sungshengtsai linagliptinandcardiovascularoutcomesintype2diabetesafteracutecoronarysyndromeoracuteischemicstroke AT dongyichen linagliptinandcardiovascularoutcomesintype2diabetesafteracutecoronarysyndromeoracuteischemicstroke AT szutahchen linagliptinandcardiovascularoutcomesintype2diabetesafteracutecoronarysyndromeoracuteischemicstroke AT juihungsun linagliptinandcardiovascularoutcomesintype2diabetesafteracutecoronarysyndromeoracuteischemicstroke AT hungyuchang linagliptinandcardiovascularoutcomesintype2diabetesafteracutecoronarysyndromeoracuteischemicstroke AT miawjeneliou linagliptinandcardiovascularoutcomesintype2diabetesafteracutecoronarysyndromeoracuteischemicstroke AT tienhsingchen linagliptinandcardiovascularoutcomesintype2diabetesafteracutecoronarysyndromeoracuteischemicstroke |